Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year, » Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
Market Commentary: Is It Time To Buy Bitcoin?
It seems that Grayscale’s spot Bitcoin ETF has been in regulatory limbo longer than a Siberian Winter due to the Securities and Exchange Commission’s (SEC) hesitance to green-light it and that’s translating to frenetic moves in crypto once again.
In a recent decision, the SEC was ordered by a U.S. appeals court to review Grayscale’s application for a spot Bitcoin ETF.
» Read more about: Market Commentary: Is It Time To Buy Bitcoin? »
Read More
1 Fast Growth Stock To Buy On The Dip
In the world of cybersecurity, Okta is synonymous with secure identity management but even the protector sometimes needs protection. The leader in identity and access management suffered not one but two high-profile breaches over the span of a single year, creating a nightmare scenario for investors.
As a leading cybersecurity company specializing in identity services,
» Read more about: 1 Fast Growth Stock To Buy On The Dip »
Read More
1 Sports Apparel Stock Set To Keep Soaring?
Few investors know that sports apparel giant, Lululemon Athletica, was originally founded as a design studio by day and yoga studio by night. Fast forward to today, and the company is nothing short of a global phenomenon that last week made it into the S&P 500 club.
But what’s on the horizon now for this extraordinary apparel firm?
» Read more about: 1 Sports Apparel Stock Set To Keep Soaring? »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read MoreThe Ivy
The $1 Trillion Buyback Boom, Who’s Spending Most to Boost Their Stock?
In February 2025 alone, corporate America saw an explosion of stock buybacks. More than 160 companies announced fresh repurchase plans—more than double the previous month’s tally. But the real story isn’t just the sheer volume; it’s who is leading the charge.
Goldman Sachs projects that S&P 500 buybacks will hit a record-breaking $1 trillion in 2025,
» Read more about: The $1 Trillion Buyback Boom, Who’s Spending Most to Boost Their Stock? »
Read MoreThe Spotlight
Will Bitcoin Rise 16.1x?
In November 2012, the first bitcoin halving cycle was recorded, and the event reduced the reward for mining new Bitcoin blocks by half. Every four years or so 210,000 blocks are mined and the rate at which new bitcoin is mined is cut by 50%.
The supply limit and increased difficulty have been instrumental in the thesis that bitcoin’s price can only rise in time to offset the inflationary effects of fiat currency.
» Read more about: Will Bitcoin Rise 16.1x? »
Read MoreThe Daily
Donald Trump is on the verge of winning his trade war
When Donald Trump decided, in early spring, to abruptly suspend his unilateral tariffs after triggering a financial panic, the Financial Times published a sarcastic comment about the US president in early May,
» Read more about: Donald Trump is on the verge of winning his trade war »